外周血单个核细胞GPSM2水平可能是肝细胞癌预后判断的新型标志物*

doi:10.3969/j.issn.1672-5069.2021.04.026

摘要/Abstract

摘要： 目的通过生物信息学方法,挖掘影响肝细胞癌(HCC)患者生存预后的关键基因,对比在外周血单个核细胞(PBMC)和肿瘤组织中关键基因水平,探索关键基因作为新型标志物判断HCC患者生存预后的价值。方法检索GEO和TCGA数据库中HCC数据,通过STRING构建蛋白质相互作用(PPI)网络和GEPIA生存验证,在Cytoscape筛选关键基因模块,对差异表达基因(DEGs)进行分析,应用Cox比例风险回归模型进行生存预后分析。结果在PBMC中分析得到DEGs 225个,其中上调基因105个,下调基因120个;通过关键模块筛选和验证,得到6个关键基因,即GPSM2、PPIL1、POLR2H、CRNKL1、U2SURP和TRA2B,这些基因在肿瘤组织中的高水平与总体生存率显著相关;应用TCGA数据库临床数据行预后分析,结果表明GPSM2高水平与III期HCC总体生存期缩短独立相关(HR=1.556,95%CI:1.153～2.100);最后,通过比对PBMC与肿瘤组织中这6个关键基因的表达水平,发现其中GPSM2、TRA2B和U2SURP在两者中的表达水平趋势相同。结论 GPSM2在HCC肿瘤组织和PBMC中的高水平与III期HCC患者预后独立相关,可能是HCC筛查和判断预后的新型标志物,甚至可成为治疗HCC的靶基因。

关键词: 肝细胞癌, 数据检索, 关键基因, 预后

Abstract: Objective The aim of this paper was to discover key genes that affect the prognosis of patients with hepatocellular carcinoma (HCC) by bioinformatics. Methods We searched the key genes in peripheral blood mononuclear cells (PBMCs) and tumor tissues in GEO and TCGA databases by using STRING to construct a protein-protein interaction (PPI) network, by using GEPIA to obtain the survival information, and by using Cytoscape to filter key gene modules for the analysis of differentially expressed genes (DEGs). The Cox proportional hazards regression model was applied for prognostic analysis. Results We obtained 225 DEGs in PBMC, of which 105 were up-regulated and 120 were down-regulated genes; out of which, six key genes were screened and verified by through key modules, e.g. GPSM2, PPIL1, POLR2H, CRNKL1, U2SURP and TRA2B; the high levels of these genes in tumor tissues was significantly related to the overall survival rate of patients; the clinical data of TCGA database were analyzed for prognosis, which showed that the GPSM2 level (HR=1.556,95%CI:1.153-2.100) was independently related to overall survival in patients with HCC stage III, and the trends of GPSM2, TRA2B and U2SURP in PBMCs were the same as in tumor tissues. Conclusion The high level of GPSM2 in HCC tumor tissues and PBMCs is independently associated with the poor prognosis of patients with HCC stage III, and it is expected this gene might become a new marker for screening and prognostic judgment of patients with HCC.

Key words: Hepatocellular carcinoma, Data retrieval, Key genes, Prognosis

于哲, 罗婧, 杨永平. 外周血单个核细胞GPSM2水平可能是肝细胞癌预后判断的新型标志物^*[J]. 实用肝脏病杂志, 2021, 24(4): 556-560.

Yu Zhe, Luo Jing, Yang Yongping. Peripheral blood mononuclear cell GPSM2 levels might be a new marker for prognosis of patients with hepatocellular carcinoma stage III[J]. Journal of Practical Hepatology, 2021, 24(4): 556-560.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Moradpoor R, Gharebaghian A, Shahi F, et al. Identification and validation of stage-associated PBMC biomarkers in breast cancer using MS-based proteomics. Front Oncol, 2020, 10:1101.
[3] Barrett T, Troup DB, Wilhite SE, et al. Ncbi geo: archive for high-throughput functional genomic data. Nucleic Acids Res, 2009, 37(Database issue):D885-890.
[4] Shi M, Chen MS, Sekar K, et al. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer, 2014, 50(5):928-936.
[5] Franceschini A, Szklarczyk D, Frankild S, et al. String v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res, 2013, 41(Database issue):D808-815.
[6] Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol, 2011, 696: 291-303.
[7] Tang Z, Li C, Kang B, et al. Gepia: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017, 45(1):W98-W102.
[8] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. the gene ontology consortium. Nat Genet, 2000, 25(1): 25-29.
[9] Ogata H, Goto S, Sato K, et al. Kegg: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res, 1999, 27(1): 29-34.
[10] 雷海科, 李小升, 赵玉兰, 等. 原发性肝癌患者生存预后及影响因素分析(附3106例报告). 中华消化外科杂志, 2020, 19(2):179-184.
[11] Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med, 2018, 12:9-26.
[12] 王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析. 实用肝脏病杂志, 2019, 22(1):118-121.
[13] He XQ, Zhang YF, Yu JJ, et al. High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. Tumour Biol, 2017, 39(3):1010428317695971.
[14] Deng M, Zhang Z, Liu B, et al. Localization of GPSM2 in the nucleus of invasive breast cancer cells indicates a poor prognosis. Front Oncol, 2020, 10:227.
[15] Deng M, Liu B, Zhang Z, et al. Knockdown of G-protein-signaling modulator 2 promotes metastasis of non-small-cell lung cancer by inducing the expression of snail. Cancer Sci, 2020, 111(9):3210-3221.
[16] Shukla S, Fisher SA. Tra2beta as a novel mediator of vascular smooth muscle diversification. Circ Res, 2008, 103(5): 485-492.
[17] Fischer DC, Noack K, Runnebaum IB, et al. Expression of splicing factors in human ovarian cancer. Oncol Rep, 2004, 11(5):1085-1090.
[18] Diao Y, Wu D, Dai Z, et al. Prognostic value of transformer 2beta expression in prostate cancer. Int J Clin Exp Pathol, 2015, 8(6):6967-6973.
[19] Gabriel B, Hausen AZ, Bouda J, et al. Significance of nuclear hTra2-beta1 expression in cervical cancer. Acta Obstet Gynecol Scand, 2009, 88(2):216-221.
[20] Watermann DO, Tang Y, Hausen AZ, et al. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res, 2006, 66(9): 4774-4780.

外周血单个核细胞GPSM2水平可能是肝细胞癌预后判断的新型标志物^*

Peripheral blood mononuclear cell GPSM2 levels might be a new marker for prognosis of patients with hepatocellular carcinoma stage III

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[2]	于雷, 孙超, 张曼旭. 灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用^*[J]. 实用肝脏病杂志, 2021, 24(4): 476-479.
[3]	鲁小龙, 解春宝. IL-6基因多态性对HBV相关ACLF患者短期预后的影响[J]. 实用肝脏病杂志, 2021, 24(4): 516-519.
[4]	金苏素, 颜华东. 血清肾上腺髓质素前体诊断失代偿期肝硬化并发细菌感染及其预测短期预后的价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 528-531.
[5]	张兵, 陈瑞红, 杨威, 徐刚. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 548-551.
[6]	王婷婷, 辛洋, 王娜娜. 肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响^*[J]. 实用肝脏病杂志, 2021, 24(4): 552-555.
[7]	高金龙, 王海峰, 李娜, 梁朝晖, 张文正. 自MR-T2图像勾画肝细胞癌患者放疗靶区精度研究[J]. 实用肝脏病杂志, 2021, 24(4): 565-568.
[8]	于涛, 李奎武, 姚琳, 吕武. 胆囊癌患者胆囊癌组织泛素结合酶E2T蛋白表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 593-596.
[9]	王梦雨, 杨蕊旭, 范建高. 重视代谢相关脂肪性肝病的特征与预后临床研究^*[J]. 实用肝脏病杂志, 2021, 24(3): 308-311.
[10]	陈晨, 王联发, 王艳, 唐郡, 张骏飞, 黄猛珣, 刘波. 112例新型冠状病毒肺炎患者肝肾功能和心肌酶学变化分析[J]. 实用肝脏病杂志, 2021, 24(3): 351-354.
[11]	刘松涛, 孟庆华, 闾军, 刘梅, 许媛, 周建新, 胡中杰. 淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析[J]. 实用肝脏病杂志, 2021, 24(3): 383-386.
[12]	孔雪杰, 李江, 李昊天, 李绪桐, 郜玉峰. 不同肝病基础的慢加急性肝衰竭患者临床特征和预后评分模型预测效能比较[J]. 实用肝脏病杂志, 2021, 24(3): 387-390.
[13]	苏亚勇, 徐成润, 郭永木, 张惠勇, 刘双平, 陈小兰. 慢加急性乙型肝炎肝衰竭患者死亡危险因素和预后评分模型的构建[J]. 实用肝脏病杂志, 2021, 24(3): 391-394.
[14]	党玲, 贾皑, 王芳. 血清内毒素结合蛋白和sCD163水平预测亚急性肝衰竭患者预后的价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 447-448.
[15]	张维娜, 丁传刚, 赵红英, 李丽, 张曼军, 卢旭. 巨细胞病毒性肝炎患儿血清IFN-γ和IL-18水平变化及其与预后的关系探讨[J]. 实用肝脏病杂志, 2021, 24(2): 208-211.